Home
About Us
Core Team
Development History
Corporate Culture
S&T
Research Areas
Technology Platforms
Research and Development
Marketed Products
R&D Products
R&D Pipeline
Academic Progress
Blog
Company News
Media Reports
Join Us
Post-Doctoral Center
Contact Us
ASCO 2022 | Major Breakthrough in Targeted Therapy for "King of Cancers" Pancreatic Cancer! Nivolumab Phase III Clinical Trial Data Unveiled!
View details
→
ASCO Live Coverage | China’s Voice Resonates Across the Globe! On-the-Record Highlights from Professors Qin Shukai and Li Jin’s Notable Research Presentation at the Conference
ASCO 2022 Highlighted Oral Presentation: Long-term Survival Results Revealed for Nivolumab in Locally Advanced Nasopharyngeal Cancer—Significant Therapeutic Efficacy
ASCO | Promising Phase 3 Clinical Results Show Significant Life Extension for Patients with Advanced Pancreatic Cancer Using EGFR Antibody Combination Therapy
[Case Share] Issue 158: Nilotinib Combined Therapy for Pediatric Choroid Plexus Papilloma
A delegation led by the Cuban Ambassador to China visited Biotech Pharma.